Aeterna Zentaris Inc (NASDAQ:AEZS)

CAPS Rating: 5 out of 5

A growing global biopharmaceutical company focused on endrocrine therapy and oncology, in drug discovery, development and commercialization.

Recs

0
Player Avatar pchop123 (78.33) Submitted: 11/19/2012 3:13:19 PM : Outperform Start Price: $1.97 AEZS Score: +8.74

Upward bound

Featured Broker Partners


Advertisement